Nationwide CT:VQ Lung Imaging Rollout Might Change The Case For Investing In 4DMedical (ASX:4DX)

Simply Wall St.

Jul 01

4DMedical Limited recently confirmed that its CT:VQ lung imaging software has received TGA approval and ARTG inclusion, clearing the way for commercial deployment across Australia using existing non-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2648593559"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2648593559\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2648593559?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","is_english":true,"pubTime":"2026-07-01 06:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648593559","market":"us","top_or_hot":-1,"title":"Nationwide CT:VQ Lung Imaging Rollout Might Change The Case For Investing In 4DMedical (ASX:4DX)","media":"Simply Wall St.","content":"<div>\n<p>4DMedical Limited recently confirmed that its CT:VQ lung imaging software has received TGA approval and ARTG inclusion, clearing the way for commercial deployment across Australia using existing non-...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/nationwide-ctvq-lung-imaging-rollout-might-change-the-case-f\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nationwide CT:VQ Lung Imaging Rollout Might Change The Case For Investing In 4DMedical (ASX:4DX)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNationwide CT:VQ Lung Imaging Rollout Might Change The Case For Investing In 4DMedical (ASX:4DX)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-01 06:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/nationwide-ctvq-lung-imaging-rollout-might-change-the-case-f><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4DMedical Limited recently confirmed that its CT:VQ lung imaging software has received TGA approval and ARTG inclusion, clearing the way for commercial deployment across Australia using existing non-...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/nationwide-ctvq-lung-imaging-rollout-might-change-the-case-f\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"4DX.AU","symbol_name":"4DMEDICAL LTD","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/nationwide-ctvq-lung-imaging-rollout-might-change-the-case-f","article_id":"2648593559","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/nationwide-ctvq-lung-imaging-rollout-might-change-the-case-f","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648593559","pubTimestamp":1782857499,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"4DMedical Limited recently confirmed that its CT:VQ lung imaging software has received TGA approval and ARTG inclusion, clearing the way for commercial deployment across Australia using existing non-contrast chest CT scans.\nThis approval materially broadens access to ventilation-perfusion imaging without radiotracers or nuclear medicine infrastructure, potentially changing how functional lung assessment is delivered across metropolitan, regional, and rural healthcare settings.\nWe’ll now...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"4DX.AU":"4DMEDICAL LTD","BK7094":"医疗保健技术","AGIX":"通用人工智能 ETF-AGIX","AIPO":"Defiance AI and Power Infrastructure ETF","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","ARTY":"ISHARES FUTURE AI & TECH ETF"},"translate_title":"全国CT：VQ肺部成像的推出可能会改变投资4DMedical(ASX：4DX)的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"4DX.AU":1.5,"ARTY":0.71,"CHAT":0.71,"AIPO":0.82,"AGIX":0.71},"content_text":"4DMedical Limited recently confirmed that its CT:VQ lung imaging software has received TGA approval and ARTG inclusion, clearing the way for commercial deployment across Australia using existing non-contrast chest CT scans. This approval materially broadens access to ventilation-perfusion imaging without radiotracers or nuclear medicine infrastructure, potentially changing how functional lung assessment is delivered across metropolitan, regional, and rural healthcare settings. We’ll now explore how nationwide CT:VQ deployment using existing CT infrastructure could influence 4DMedical’s previously assessed investment narrative. AI is about to change healthcare. These 9 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Advertisement4DMedical Investment Narrative RecapTo own 4DMedical, you need to believe its lung imaging software can convert regulatory clearances into recurring, high-margin scan volumes before cash burn and dilution pressure the business. The CT:VQ TGA approval strengthens the near term commercialisation catalyst in Australia, but does not remove the key risks around ongoing losses, negative equity and the need to justify recent capital raises with tangible revenue traction. Among recent announcements, the GSK collaboration using CT:VQ biomarkers for pulmonary drug development stands out as closely linked to this approval, as both hinge on real world adoption of the same core platform. Together, pharma usage and Australian commercial rollout sit at the heart of the thesis that 4DMedical can scale CT:VQ beyond early lighthouse sites and transition from primarily promise to meaningful operating cash inflows. However, in contrast to the regulatory momentum, investors should be aware that the company’s reliance on future capital raises and currently negative equity position could... Read the full narrative on 4DMedical (it's free!)4DMedical's narrative projects A$72.4 million revenue and A$9.1 million earnings by 2029. This requires 131.9% yearly revenue growth and about a A$182.0 million earnings increase from -A$172.9 million today.Uncover how 4DMedical's forecasts yield a A$4.97 fair value, a 10% upside to its current price.Exploring Other PerspectivesASX:4DX 1-Year Stock Price Chart Eight fair value estimates from the Simply Wall St Community range widely, from A$0.36 to A$11.11 per share, showing how far apart individual views can be. You are weighing these against a company that is still burning cash and relying on successful CT:VQ rollout to support its developing commercial story, so it can be useful to compare several of these alternative viewpoints before forming your own view.Explore 8 other fair value estimates on 4DMedical - why the stock might be worth less than half the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your 4DMedical research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.Our free 4DMedical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 4DMedical's overall financial health at a glance.Searching For A Fresh Perspective?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.We've uncovered the 5 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}